Novartis India Reports Strong Profit Growth Amid Concerns Over Non-Operating Income Sustainability in March 2025

May 09 2025 09:02 PM IST
share
Share Via
Novartis India has announced its financial results for the quarter ending March 2025, highlighting significant growth in Profit Before Tax (PBT) and Profit After Tax (PAT), both reaching their highest levels in five quarters. The company also noted an increase in Non-Operating Income, raising questions about its sustainability.
Novartis India has recently reported its financial results for the quarter ending March 2025, showcasing notable developments in its performance metrics. The company's score has undergone an adjustment, reflecting a shift in evaluation from the previous quarter.

Key highlights from the financial results indicate a significant growth in Profit Before Tax (PBT), which reached Rs 23.26 crore, marking a year-on-year increase of 113.20%. This positive trend in PBT suggests a robust operational performance. Similarly, Profit After Tax (PAT) also demonstrated strong growth, amounting to Rs 29.30 crore, a 99.6% increase year-on-year, and representing the highest PAT recorded in the last five quarters. The Earnings per Share (EPS) reached Rs 11.87, the highest in the same timeframe, indicating enhanced profitability for shareholders.

However, it is important to note that the company reported its highest Non-Operating Income at Rs 10.63 crore in the last five quarters. This increase, while notable, raises questions about the sustainability of income derived from non-business activities.

Overall, Novartis India's financial results reflect a complex landscape of growth and potential challenges.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Why is Novartis India falling/rising?
Dec 05 2025 12:56 AM IST
share
Share Via
Why is Novartis India falling/rising?
Nov 06 2025 10:05 PM IST
share
Share Via
Is Novartis India overvalued or undervalued?
Nov 05 2025 08:06 AM IST
share
Share Via
Is Novartis India overvalued or undervalued?
Nov 03 2025 08:04 AM IST
share
Share Via
Is Novartis India overvalued or undervalued?
Nov 02 2025 08:04 AM IST
share
Share Via